Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2025-07-30 Capital/Financing Update
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Trading Halt 3 pages 359.6KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Nyrada Inc regarding a trading halt requested pending the release of an announcement about a proposed capital raising. It is dated 31 July 2025 and is a formal request to the ASX for a trading halt under ASX Listing Rule 17.1. The text does not contain any financial statements, detailed financial data, or report content. Instead, it is a short notice about the trading halt and the reason for it, which is the upcoming capital raising announcement. The document length is 4303 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, this type of document fits best under Capital/Financing Update (CAP) because it relates to a capital raising event and trading halt associated with it. It is not a report publication announcement (RPA) because it does not mention the release of a report but rather a trading halt pending an announcement. Therefore, the correct classification is CAP with high confidence.
2025-07-30 English
Change in substantial holding - M Azzi 2 pages 240.3KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Notice of Change of Interests of Substantial Securityholder' and details changes in the voting power and holdings of a substantial shareholder, Mr. Mark Azzi, in Nyrada Inc. It includes specific numbers of shares/CDIs held before and after the change, and references relevant sections of the Corporations Act 2001 (Cth). The content focuses on notifying the market and regulatory bodies about changes in significant share ownership levels. There is no financial performance data, audit information, or management discussion. The document is not an announcement of a report publication but a direct notice of shareholding changes. Therefore, the document fits the category of Major Shareholding Notification (MRQ). The document length is 4054 characters, which is consistent with a detailed notification rather than a brief announcement or a full report.
2025-07-30 English
NYR Advances Xolatryp Phase IIa Trial in Cardioprotection 5 pages 304.7KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Nyrada Inc. about advancing their drug candidate Xolatryp into a Phase IIa clinical trial. It includes information on trial design, strategic focus, market opportunity, and recent Phase I trial progress. The content is focused on clinical development updates and strategic plans rather than financial results, governance changes, or regulatory filings. It is not a financial report, earnings release, or regulatory filing. The document is a corporate announcement about clinical trial progress and plans, which fits best under the category of a general regulatory announcement or corporate update. Given the absence of financial statements or detailed financial data, and the nature of the content being an update on clinical trial progress and company strategy, the most appropriate classification is Regulatory Filings (RNS). The document length (over 11,000 characters) and detailed content confirm it is not a brief announcement or a report publication announcement.
2025-07-22 English
Final Phase I Clinical Trial Patients Dosed and Discharged 4 pages 306.4KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the completion of dosing in a Phase I clinical trial for a drug called Xolatryp by Nyrada Inc. It provides clinical trial progress updates, safety information, and background on the drug and company. There are no financial statements, earnings data, or regulatory filings related to financial performance. The content is focused on clinical trial progress and company development updates rather than financial or governance matters. It is not a report like an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a regulatory filing or certification. The document is a corporate announcement providing an update on clinical trial progress and related scientific data, which fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2025-07-20 English
Final Nyrada Phase I Clinical Trial Cohort to Commence 4 pages 305.9KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the progress of a Phase I clinical trial for a drug called Xolatryp by Nyrada Inc. It provides updates on trial cohorts, safety reviews, and preclinical study results. The content is focused on clinical trial progress and scientific data rather than financial results or regulatory filings. It does not contain financial statements, earnings data, or management discussion of financial results. It is not a regulatory filing, audit report, or management change announcement. The document is a corporate announcement about clinical trial progress, which does not fit into financial report categories but is best classified as a general regulatory announcement or miscellaneous filing. Given the absence of financial or governance content, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2025-07-13 English
Notice of Change of Interests of Substantial Holder - M Azzi 2 pages 226.6KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Notice of Change of Interests of Substantial Securityholder' and details changes in the voting power and holdings of a substantial shareholder, Mr. Mark Azzi. It includes specific numbers of shares/CDIs held before and after the change, and references relevant sections of the Corporations Act 2001 (Cth). There is no financial performance data, earnings information, or management discussion. The document is a formal notification of a change in significant share ownership levels, which fits the definition of 'Major Shareholding Notification'. The document length is 4018 characters, which is consistent with a notice rather than a full report. Therefore, the appropriate classification is MRQ (Major Shareholding Notification).
2025-07-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.